Cullinan Therapeutics, Inc. (CGEM) Investor Relations Documents

Cullinan Therapeutics, Inc. (CGEM) investor relations documents from the company's IR site: 1 presentation, 16 press releases; latest deck 2026-06-10. Read in-app with summaries. First-party data.

Immunology Day Event - June 10, 2026 — Cullinan Therapeutics' Immunology Day outlines a T cell engager (TCE) strategy for autoimmune diseases, highlighting CLN-978 and Velinotamig for immune reset.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-19Press releaseZipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation
2026-08-12Press releaseZipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase
2026-08-06Press releaseCullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-07-28Press releaseCullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potential
2026-06-10PresentationImmunology Day Event - June 10, 2026
2026-06-10Press releaseJune 10, 2026 Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting C
2026-06-06Press releaseCullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
2026-05-26Press releaseCullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-
2026-05-19Press releaseCullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Ref
2026-05-18Press releaseCullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Syst
2026-05-07Press releaseCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
2026-04-28Press releaseU.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or
2026-03-10Press releaseCullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-24Press releaseCullinan Therapeutics to Participate in Upcoming Investor Conferences
2026-02-18Press releaseCullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
2026-02-05Press releaseCullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
2026-01-08Press releaseCullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

CGEM overview · CGEM earnings · CGEM financials · CGEM KPIs · CGEM ownership · CGEM peers · CGEM filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.